Translational Development Acquisition Corp. Files S-1/A Amendment

TL;DR

SPAC filing update. TDAC is moving forward with its registration.

AI Summary

Translational Development Acquisition Corp. filed an S-1/A amendment on November 20, 2024, related to its registration statement (No. 333-282763). The company, incorporated in the Cayman Islands, is a blank check company with its principal executive offices located at 52 E 83rd St., New York, NY 10028. Michael B. Hoffman is listed as the CEO.

Why It Matters

This filing indicates an update to the company's registration, which is a step in its process to potentially pursue a business combination or acquisition.

Risk Assessment

Risk Level: low — This is a routine amendment to a registration statement, not indicating immediate financial distress or significant new risks.

Key Numbers

• 333-282763 — SEC File Number (Identifies the specific registration filing)

Key Players & Entities

• Translational Development Acquisition Corp. (company) — Registrant
• 333-282763 (registration_number) — SEC File Number
• November 20, 2024 (date) — Filing Date
• Michael B. Hoffman (person) — CEO
• 52 E 83rd St., New York, NY 10028 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $150,000,000 — ational Development Acquisition Corp. $150,000,000 15,000,000 Units Translational Deve
• $10.00 — ies. Each unit has an offering price of $10.00 and consists of one Class A ordinary sh
• $11.50 — ne Class A ordinary share at a price of $11.50 per share, subject to adjustment as des
• $1.00 — e, subject to adjustment, at a price of $1.00 per warrant, or $5,650,000 (or $6,212,5
• $5,650,000 — nt, at a price of $1.00 per warrant, or $5,650,000 (or $6,212,500 if the underwriters' ove
• $6,212,500 — of $1.00 per warrant, or $5,650,000 (or $6,212,500 if the underwriters' over-allotment opt
• $2,162,500 — rrants at a price of $1.00 per warrant ($2,162,500 in the aggregate) in a private placemen
• $25,000 — Our former sponsor paid an aggregate of $25,000, or approximately $0.006 per founder sh
• $0.006 — aggregate of $25,000, or approximately $0.006 per founder share, and, accordingly, yo
• $0.05 — funded extension period, an additional $0.05 per unit (for an aggregate of $750,000,
• $750,000 — nal $0.05 per unit (for an aggregate of $750,000, or $862,500 if the underwriters' over-
• $862,500 — unit (for an aggregate of $750,000, or $862,500 if the underwriters' over-allotment opt
• $100,000 — unt and (net of taxes payable and up to $100,000 of interest to pay dissolution expenses
• $0.20 — 9.45 $ 141,750,000 1) Includes $0.20 per unit (including any units sold purs
• $3,000,000 — ption to purchase additional units), or $3,000,000 in the aggregate (or up to $3,450,000 i

Filing Documents

• tm2422367-6_s1a.htm (S-1/A) — 2596KB
• tm2422367d7_ex1-1.htm (EX-1.1) — 256KB
• tm2422367d7_ex3-2.htm (EX-3.2) — 260KB
• tm2422367d7_ex4-1.htm (EX-4.1) — 17KB
• tm2422367d7_ex4-2.htm (EX-4.2) — 15KB
• tm2422367d7_ex4-3.htm (EX-4.3) — 23KB
• tm2422367d7_ex4-4.htm (EX-4.4) — 95KB
• tm2422367d7_ex5-1.htm (EX-5.1) — 36KB
• tm2422367d7_ex5-2.htm (EX-5.2) — 18KB
• tm2422367d7_ex10-4.htm (EX-10.4) — 46KB
• tm2422367d7_ex10-5.htm (EX-10.5) — 82KB
• tm2422367d7_ex10-6.htm (EX-10.6) — 101KB
• tm2422367d7_ex10-8.htm (EX-10.8) — 43KB
• tm2422367d7_ex10-9.htm (EX-10.9) — 46KB
• tm2422367d7_ex10-10.htm (EX-10.10) — 98KB
• tm2422367d7_ex10-11.htm (EX-10.11) — 10KB
• tm2422367d7_ex14.htm (EX-14) — 56KB
• tm2422367d7_ex23-1.htm (EX-23.1) — 4KB
• tm2422367d7_ex99-1.htm (EX-99.1) — 45KB
• tm2422367d7_ex99-2.htm (EX-99.2) — 29KB
• tm2422367d7_ex99-3.htm (EX-99.3) — 31KB
• tm2422367d7_ec5-1img001.jpg (GRAPHIC) — 11KB
• tm2422367d7_ex23-1img01.jpg (GRAPHIC) — 6KB
• tm2422367d7_ex23-1img02.jpg (GRAPHIC) — 11KB
• tm2422367d7_ex5-2img003.jpg (GRAPHIC) — 39KB
• tm2422367d7_img004.jpg (GRAPHIC) — 19KB
• 0001104659-24-120690.txt ( ) — 4028KB

Use of Proceeds

Use of Proceeds 101 Dividend Policy 105

Dilution

Dilution 106 Capitalization 110

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 112 Proposed Business 119 Effecting our Initial Business Combination 130 Management 153 Principal Shareholders 163 Certain Relationships and Related Party Transactions 168

Description of Securities

Description of Securities 171 Taxation 193

Underwriting

Underwriting 205 Legal Matters 216 Experts 216 Where You Can Find Additional Information 216 Index to Financial Statements F-1 We are responsible for the information contained in this prospectus. We have not, and the underwriters have not, authorized anyone to provide you with information that is different from or inconsistent with that contained in this prospectus. We are not, and the underwriters are not, making an offer to sell securities in any jurisdiction where the offer or sale is not permitted. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front of this prospectus. i TABLE OF CONTENTS Trademarks This prospectus contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the or symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. TABLE OF CONTENTS SUMMARY This summary only highlights the more detai

View Full Filing

View this S-1/A filing on SEC EDGAR